Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target at $9.40

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been assigned an average recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $9.40.

Several brokerages have weighed in on RXRX. Needham & Company LLC reduced their price objective on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Jefferies Financial Group dropped their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. KeyCorp dropped their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Leerink Partners dropped their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd.

Insider Buying and Selling

In related news, COO Tina Marriott sold 6,000 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total value of $45,360.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,939,803.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $6.35, for a total value of $95,250.00. Following the sale, the chief financial officer now owns 1,340,968 shares in the company, valued at approximately $8,515,146.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the sale, the chief operating officer now owns 521,138 shares in the company, valued at $3,939,803.28. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 195,682 shares of company stock worth $1,284,153. Corporate insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in RXRX. Vanguard Group Inc. raised its position in Recursion Pharmaceuticals by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 15,665,210 shares of the company’s stock valued at $154,459,000 after purchasing an additional 158,376 shares in the last quarter. Oxinas Partners Wealth Management LLC purchased a new stake in Recursion Pharmaceuticals during the first quarter valued at about $122,000. Sumitomo Mitsui Trust Holdings Inc. raised its position in Recursion Pharmaceuticals by 12.6% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company’s stock valued at $103,317,000 after purchasing an additional 1,159,023 shares in the last quarter. Azzad Asset Management Inc. ADV purchased a new stake in Recursion Pharmaceuticals during the first quarter valued at about $161,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in Recursion Pharmaceuticals during the first quarter valued at about $26,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $6.48 on Wednesday. The stock has a fifty day simple moving average of $6.72 and a two-hundred day simple moving average of $7.71. Recursion Pharmaceuticals has a 1-year low of $4.97 and a 1-year high of $15.74. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -4.00 and a beta of 0.80. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same period last year, the company posted ($0.38) earnings per share. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% on a year-over-year basis. Analysts anticipate that Recursion Pharmaceuticals will post -1.58 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.